Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 31, 2023 09:00 ET | Source: Eyenovia

Eyenovia Showcases Microdose Array Print (MAP™) Technology at CES 2023 in Las Vegas

LAS VEGAS, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in connection with its...
December 22, 2022 09:01 ET | Source: Eyenovia

Eyenovia Aims to Revolutionize Ophthalmology Devices With Microdose Array Print (MAP) Technology

NEW YORK, Dec. 22, 2022 (GLOBE NEWSWIRE) -- While medical devices have seen incredible advancements over the last 100 years, ocular drug delivery systems have seen minimal progress; the standard eye...
October 17, 2022 09:01 ET | Source: Eyenovia

Investigational Optejet® Microdose Dispenser from Eyenovia Shows Promise in Improving Treatment for Myopia, Presbyopia and Patients Getting Eye Exams

NEW YORK, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Two recent studies show that the novel Optejet® dispenser from Eyenovia, Inc., an ophthalmic pharmaceutical technology company, may be a more...
September 21, 2022 10:01 ET | Source: Eyenovia

Eyenovia Chairman Dr. Sean Ianchulev: The Making Of An iDoctor - Immigrant, Innovator, Inventor

NEW YORK, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Before founding Eyenovia, Dr. Sean Ianchulev had established himself as a pioneer and innovator in the field of ophthalmology. Inspired by his mother, a...
August 30, 2022 09:01 ET | Source: Eyenovia

Eyenovia's Novel Optejet® Dispenser Puts People's Eyes First

NEW YORK, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) therapeutics, brings...
September 24, 2018 19:22 ET | Source: Bragar Eagel & Squire

Bragar Eagel & Squire, P.C. Reminds Investors that it is Investigating Possible Securities Fraud Violations by Certain Officers and Directors of Menlo Therapeutics, Hill International, and Eyenovia on Behalf of Stockholders and Encourages Investors to Contact the Firm

NEW YORK, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. reminds investors that it is investigating potential claims on behalf of stockholders of Menlo Therapeutics Inc., Hill...
August 17, 2018 15:39 ET | Source: Bragar Eagel & Squire

Bragar Eagel & Squire, P.C. is Investigating Eyenovia, Inc. (EYEN) on Behalf of Stockholders and Encourages Investors to Contact the Firm

NEW YORK, Aug. 17, 2018 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. is investigating potential claims against Eyenovia, Inc. (NASDAQ: EYEN). Our investigation concerns whether Eyenovia has...
November 28, 2016 15:46 ET | Source: Eyenovia, Inc

Eyenovia, Inc. announces publication of Phase II study results demonstrating benefits of micro-formulation over conventional eyedroppers and addition of Scientific Advisory Board members

Eyenovia’s study shows that conventional ophthalmic eye drops significantly overdose the eye and that equivalent, or greater, pharmacodynamic effect can be achieved with 80% less ocular exposure...